At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 90 enrolled
Drug / intervention
Bupivacaine +2 moredrug
Likely dose
Saline 60 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mixture of Liposomal Bupivicaine and Bupivicaine Hydrogen Chloride (HCl) May Provide Faster and Longer Lasting Analgesia in Transversus Abdominis Block for Patient Having Open Abdominal Hysterectomies
In Brief
A Phase 4 clinical trial evaluating Bupivacaine, Liposomal bupivacaine, and 1 other intervention for Hysterectomy. Completed, enrolled 90 participants across 1 site.
Detailed Summary
The goal of this study is to evaluate the effectiveness of different formulations of bupivacaine infiltrated into the transversus abdominis plane (TAP) on post-operative pain management after open abdominal hysterectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHysterectomy
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
First PostedAug 2017
Primary CompletionJan 2019
TodayJul 2026
First PostedAug 15, 2017
Enrollment StartMar 13, 2017
Primary CompletionJan 30, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.9 years ago
Interventions
Bupivacainedrug
0.25% bupivacaine for TAP block
Liposomal bupivacainedrug
Exparel for TAP block
Salinedrug
Saline for TAP block that will be mixed with liposomal bupivacaine to bring the liposomal bupivacaine group to 60 mL total volume.